Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma

References

• King RL, Goodlad JR, Calaminici M, et al. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Archiv. 2020;476(5):647–665. doi:10.1007/s00428-019-02698-3
   PubMed Web of Science ®Google Scholar
• Møller MB, d’Amore F, Christensen BE, Group DLS. Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis. EUR J Cancer. 1994;30(12):1760–1764.
   Google Scholar
• Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21(1):20–27. doi:10.1200/JCO.2003.11.141
   PubMed Web of Science ®Google Scholar
• Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood. 2014;123(4):486–493. doi:10.1182/blood-2013-10-530659
   PubMed Web of Science ®Google Scholar
• Gundrum JD, Mathiason MA, Moore DB, Go RS. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009;27(31):5227–5232. doi:10.1200/JCO.2009.22.5896
   PubMed Web of Science ®Google Scholar
• Verma N, Lazarchick J, Gudena V, Turner J, Chaudhary UB. Testicular lymphoma: an update for clinicians. Am J Med Sci. 2008;336(4):336–341. doi:10.1097/MAJ.0b013e31817242bc
   PubMed Web of Science ®Google Scholar
• Visco C, Medeiros LJ, Mesina OM, et al. Non-Hodgkin’s lymphoma affecting the testis: is it curable with doxorubicin-based therapy? Clin Lymphoma. 2001;2(1):40–46. doi:10.3816/CLM.2001.n.010
   PubMedGoogle Scholar
• Kridel R, Telio D, Villa D, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Br J Haematol. 2017;176(2):210–221. doi:10.1111/bjh.14392
   PubMed Web of Science ®Google Scholar
• Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international Phase II trial. J Clin Oncol. 2011;29(20):2766–2772. doi:10.1200/JCO.2010.31.4187
   PubMed Web of Science ®Google Scholar
• Linassier C, Desablens B, Lefrancq T, et al. Stage I-IIE primary non-Hodgkin’s lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group. Clin Lymphoma. 2002;3(3):167–172. doi:10.3816/CLM.2002.n.023
   PubMedGoogle Scholar
• Seymour JF, Solomon B, Wolf MM, Janusczewicz EH, Wirth A, Prince HM. Primary large-cell non-Hodgkin’s lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. Clin Lymphoma. 2001;2(2):109–115. doi:10.3816/CLM.2001.n.016
   PubMedGoogle Scholar
• Lantz AG, Power N, Hutton B, Gupta R. Malignant lymphoma of the testis: a study of 12 cases. Can Urol Assoc J. 2009;3(5):393–398. doi:10.5489/cuaj.1153
   PubMed Web of Science ®Google Scholar
• Mazloom A, Fowler N, Medeiros LJ, Iyengar P, Horace P, Dabaja BS. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma. 2010;51(7):1217–1224. doi:10.3109/10428191003793358
   PubMed Web of Science ®Google Scholar
• Telio D, Villa D, Shenkier T, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Blood. 2011;118(21):780. doi:10.1182/blood.V118.21.780.780
   Google Scholar
• Mazloom A, Fowler N, Iyengar P, Dabaja BS. Primary testicular diffuse large B-cell lymphoma, M.D. Anderson Cancer Center experience. Blood. 2009;114(22):2697. doi:10.1182/blood.V114.22.2697.2697
   Web of Science ®Google Scholar
• Deng L, Xu-Monette Z, Loghavi S, et al. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia. 2016;30(2):361–372. doi:10.1038/leu.2015.237
   PubMed Web of Science ®Google Scholar
• Conconi A, Chiappella A, Orsucci L, et al. Intensified (Intravenous and Intrathecal) CNS prophylaxis in primary testicular diffuse large B-cell lymphoma: 5-year results of the IELSG30 trial. Hematol Oncol. 2021;39(S2). doi:10.1002/hon.48_2879
   Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545
   PubMed Web of Science ®Google Scholar
• Riedell PA, Smith SM. Double hit and double expressors in lymphoma: definition and treatment. Cancer. 2018;124(24):4622–4632. doi:10.1002/cncr.31646
   PubMed Web of Science ®Google Scholar
• Hyeon J, Lee B, Shin SH, et al. Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement. Modern Pathol. 2018;31(9):1418–1428. doi:10.1038/s41379-018-0064-0
   PubMed Web of Science ®Google Scholar
• Shin HT, Choi YL, Yun JW, et al. Prevalence and detection of low-allele-fraction variants in clinical cancer samples. Nat Commun. 2017;8(1):1377. doi:10.1038/s41467-017-01470-y
   PubMedGoogle Scholar
• Wilm A, Aw PP, Bertrand D, et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 2012;40(22):11189–11201. doi:10.1093/nar/gks918
   PubMed Web of Science ®Google Scholar
• Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213–219. doi:10.1038/nbt.2514
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800
   PubMed Web of Science ®Google Scholar
• Chapuy B, Roemer MG, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–881. doi:10.1182/blood-2015-10-673236
   PubMed Web of Science ®Google Scholar
• Ho JC, Dabaja BS, Milgrom SA, et al. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017;58(12):2833–2844. doi:10.1080/10428194.2017.1312381
   PubMed Web of Science ®Google Scholar
• Park BB, Kim JG, Sohn SK, et al. Consideration of aggressive therapeutic strategies for primary testicular lymphoma. Am J Hematol. 2007;82(9):840–845. doi:10.1002/ajh.20973
   PubMed Web of Science ®Google Scholar
• Fonseca R, Habermann TM, Colgan JP, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000;88(1):154–161. doi:10.1002/(SICI)1097-0142(20000101)88:1<154::AID-CNCR21>3.0.CO;2-T
   PubMed Web of Science ®Google Scholar
• Yan Z, Yao S, Wang Y, Liu Y, Yao Z. Primary testicular lymphoma with central nervous system relapse was successfully treated by a chemo-free regimen: a case report and literature review. Cancer Manag Res. 2021;13:9489–9500. doi:10.2147/CMAR.S341342
   PubMed Web of Science ®Google Scholar
• Balis FM, Blaney SM, McCully CL, Bacher JD, Murphy RF, Poplack DG. Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol. 2000;45(3):259–264. doi:10.1007/s002800050038
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25(11):1350–1356. doi:10.1200/JCO.2006.09.7311
   PubMed Web of Science ®Google Scholar
• Batchelor T, Leahy N, Kaufman D. High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin’s lymphoma. Clin Lymphoma. 2001;2(2):116–9; discussion 20–2. doi:10.3816/CLM.2001.n.017
   PubMedGoogle Scholar
• Avilés A, Nambo MJ, Cleto S, Neri N, Huerta-Guzmán J. Rituximab and dose-dense chemotherapy in primary testicular lymphoma. Clin Lymphoma Myeloma. 2009;9(5):386–389. doi:10.3816/CLM.2009.n.075
   PubMedGoogle Scholar
• Twa DDW, Lee DG, Tan KL, et al. Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma. Blood. 2021;137(9):1256–1259. doi:10.1182/blood.2020006338
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–926. doi:10.1038/nm.3884
   PubMed Web of Science ®Google Scholar